Current status of pharmaceutical and genetic therapeutic approaches to treat DMD
Duchenne muscular dystrophy (DMD) is a genetic disease affecting about one in every 3,500 boys. This X-linked pathology is due to the absence of dystrophin in muscle fibers. This lack of dystrophin leads to the progressive muscle degeneration that is often responsible for the death of the DMD patien...
المؤلفون الرئيسيون: | Pichavant, C, Aartsma-Rus, A, Clemens, P, Davies, K, Dickson, G, Takeda, S, Wilton, S, Wolff, J, Wooddell, C, Xiao, X, Tremblay, J |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
2011
|
مواد مشابهة
-
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.
حسب: Pichavant, C, وآخرون
منشور في: (2011) -
Utrophin upregulation in DMD therapy: current status and new tools for the future
حسب: Fairclough, R, وآخرون
منشور في: (2011) -
DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
حسب: Remko Goossens, وآخرون
منشور في: (2023-12-01) -
BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model
حسب: SongTing Shi, وآخرون
منشور في: (2011-02-01) -
DMD and West syndrome
حسب: Cardas, R, وآخرون
منشور في: (2017)